{"id":4463,"date":"2025-09-09T18:11:34","date_gmt":"2025-09-09T15:11:34","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=4463"},"modified":"2025-09-09T18:11:35","modified_gmt":"2025-09-09T15:11:35","slug":"belief-biomed-announced-successful-completion-of-first-dose-of-bbm-d101-gene-therapy","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/pt\/belief-biomed-announced-successful-completion-of-first-dose-of-bbm-d101-gene-therapy\/","title":{"rendered":"Belief BioMed anuncia conclus\u00e3o bem-sucedida da primeira dose da terapia gen\u00e9tica BBM-D101"},"content":{"rendered":"<p class=\"wp-block-paragraph\">A Belief BioMed, uma empresa de biotecnologia inovadora focada no desenvolvimento de terapias gen\u00e9ticas de ponta, anunciou hoje que o ensaio cl\u00ednico de registro (CTR20252461) de sua inje\u00e7\u00e3o BBM-D101 desenvolvida e produzida de forma independente para Distrofia Muscular de Duchenne (DMD) concluiu com sucesso a primeira dosagem em pacientes em Pequim, China.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">A inje\u00e7\u00e3o de BBM-D101, uma terapia gen\u00e9tica baseada em AAV, utiliza um caps\u00eddeo projetado para atingir tecidos musculares de forma eficiente. Administrada em uma dose menor do que as contrapartes estrangeiras comercializadas, espera-se que ofere\u00e7a seguran\u00e7a favor\u00e1vel. O IND para BBM-D101 foi aprovado pela Administra\u00e7\u00e3o Nacional de Produtos M\u00e9dicos (NMPA) da China e pela Administra\u00e7\u00e3o de Alimentos e Medicamentos (FDA) dos Estados Unidos em 2025.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Saber mais<\/strong>: <a href=\"https:\/\/dmdwarrior.com\/pt\/belief-biomed-bbm-d101-gene-therapy-phase-1-2-clinical-trial-nct07058662\/\" target=\"_blank\" rel=\"noreferrer noopener\">In\u00edcio do ensaio cl\u00ednico de fase 1\/2 da terapia gen\u00e9tica BBM-D101<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Belief BioMed, an innovative biotechnology company focused on developing cutting-edge gene therapies, today announced that the registration clinical trial (CTR20252461) of its independently developed and produced BBM-D101 injection for Duchenne Muscular Dystrophy (DMD) has successfully completed the first patient dosing in Beijing, China. BBM-D101 injection, an AAV-based gene therapy, utilizes an engineered capsid to efficiently [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":4464,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[281],"tags":[199,197,123,137,242,61],"class_list":["post-4463","post","type-post","status-publish","format-standard","has-post-thumbnail","category-press-releases","tag-bbm-d101","tag-belief-biomed","tag-china","tag-clinical-trial","tag-clinical-trials","tag-gene-therapy"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/posts\/4463","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/comments?post=4463"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/posts\/4463\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/media\/4464"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/media?parent=4463"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/categories?post=4463"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/tags?post=4463"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}